Michael Krainer

Medical University of Vienna — Austria

Medicine · Health Sciences

39h-index7.1kcitations206works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(44), Ovarian cancer diagnosis and treatment(23), Cancer Treatment and Pharmacology(17), Radiopharmaceutical Chemistry and Applications(16), Cancer, Hypoxia, and Metabolism(15)

Publications206 total

Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer
Clinical & Experimental Metastasis·2024· 5 citedOpen Access
Supplementary Figure 4 from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure Legend from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Tables from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure 2 from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Tables from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure 3 from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Data from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure 1 from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Data from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure Legend from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure 3 from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure 2 from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure 1 from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Supplementary Figure 4 from HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
2023Open Access
Data from Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer
2023Open Access
Data from Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer
2023Open Access
Data from hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer
2023Open Access
Supplementary Figure 2 from hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer
2023Open Access
Supplementary Figure Legends 1-5 from hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Dietmar Pils(14), Robert Zeillinger(14), Peter Horak(13), Christoph Zielinski(12), Reinhard Horvat(9), Daniel A. Haber(6), Wolfgang J. Köstler(6), Stéphane Oudard(5), Alexander Reinthaller(5), Maximilian Marhold(5), Petr Vaňhara(5), Mariam Anees(5), Karim Fizazi(4), Andries M. Bergman(4), Tomasz M. Beer(4), Michael G. FitzGerald(4), Kurt J. Isselbacher(4), Ingrid Pribill(4), Sandra Tomek(4), Christoph Wiltschke(4)